Scarica l'app Stockscreener
0.6971
8.92%
0.0571
Dopo l'orario di chiusura:
.70
0.0029
+0.42%
Fibrobiologics Inc Borsa (FBLG) Ultime notizie
Why FibroBiologics Inc. stock attracts strong analyst attentionMassive Gain Ideas - Newser
What makes FibroBiologics Inc. stock price move sharply2x Return Forecast - Newser
How FibroBiologics Inc. stock performs during market volatilityFree Stock Investment Growth Plan - Newser
FibroBiologics (NASDAQ:FBLG) vs. Neumora Therapeutics (NASDAQ:NMRA) Head to Head Contrast - Defense World
Brag House and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Fall River Herald News
FibroBiologics to Present at the Advanced Wound Care Summit USA - GlobeNewswire
FibroBiologics Reveals Breakthrough Diabetic Foot Ulcer Treatment Ahead of Phase 1/2 Trial - Stock Titan
FibroBiologics Inc. (NASDAQ:FBLG) Receives Consensus Rating of “Buy” from Brokerages - Defense World
D. Boral Capital Reaffirms “Buy” Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
Disc Medicine,Inc. shares rise 1.54% after-hours as FibroBiologics advances cartilage repair program. - AInvest
Fibrobiologics Confirms Ability to Manufacture Cybrocell for Degenerative Disc Disease and Cartilage Repair Programs from Existing Cywc628 Master Cell Bank - MarketScreener
FibroBiologics announces advancement in its cartilage repair program - TipRanks
FibroBiologics Confirms Ability to Manufacture CybroCell™ - GlobeNewswire
Breakthrough: FibroBiologics Achieves Major Cost-Saving Milestone in Degenerative Disc Disease Treatment Development - Stock Titan
FibroBiologics Webinar: A Crossroads for Pipeline Progress and IP Dominance in Cell Therapy - AInvest
FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform - Nasdaq
FibroBiologics’ to Present at Exclusive Live Investor Webinar and Q&A Session on July 10 - GlobeNewswire
FibroBiologics to Reveal Next-Gen Cell Therapy Platform: 275+ Patents Target Billion-Dollar Markets - Stock Titan
Disruptive Innovation and Clinical Breakthroughs: Fathom Holdings and FibroBiologics Lead the Charge - AInvest
Fathom Holdings and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Worcester Telegram
FibroBiologics, Inc.(NasdaqCM: FBLG) dropped from Russell 2000 Index - MarketScreener
Is FibroBiologics, Inc. technically bullish or bearish? - MarketsMojo
FibroBiologics Inc (NASDAQ: FBLG) Has Great Upside Potential - Stocksregister
Fibrobiologics closes third $5 mln tranche of $25 mln financing - MarketScreener
FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing - GlobeNewswire
FibroBiologics Raises $25M to Launch Breakthrough Diabetic Foot Ulcer Treatment Trial - Stock Titan
FibroBiologics to Present Company Update and Research Advances at BIO International Convention 2025 - Nasdaq
FibroBiologics to Present at the BIO International Convention 2025 - GlobeNewswire
Clinical Trial Alert: FibroBiologics Unveils Groundbreaking Fibroblast Treatment for Chronic Disease at BIO 2025 - Stock Titan
FibroBiologics, Inc. (NASDAQ:FBLG) Receives Consensus Rating of “Buy” from Brokerages - Defense World
FibroBiologics names new CFO after going public last year - The Business Journals
FibroBiologics appoints new CFO amid clinical trials By Investing.com - Investing.com South Africa
FibroBiologics, Inc. Appoints Jason D. Davis as Chief Financial Officer, Effective June 9, 2025 - MarketScreener
FibroBiologics appoints Jason Davis as CFO - TipRanks
FibroBiologics Appoints Jason Davis As CFO - Nasdaq
FibroBiologics appoints new CFO amid clinical trials - Investing.com Australia
FibroBiologics, Inc. Appoints Jason D. Davis as Chief Financial Officer to Drive Growth and Clinical Development - Nasdaq
FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer - GlobeNewswire
FibroBiologics Taps Former Virax IPO Leader as CFO Ahead of Critical Clinical Trials - Stock Titan
Jane Street Group LLC Acquires 49,222 Shares of FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
Top Executive Makes Bold Move with Major Stock Purchase in FibroBiologics! - TipRanks
FibroBiologics, Inc. (NASDAQ:FBLG) Receives $13.00 Consensus PT from Analysts - Defense World
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis - Research Tree
FBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis… - Zacks Small Cap Research
FibroBiologics Presents at the Society for Investigative Dermatology Annual Meeting - GlobeNewswire
D. Boral Capital Reiterates Buy Rating for FibroBiologics (NASDAQ:FBLG) - Defense World
FibroBiologics Presents Research on Human Dermal Fibroblast Spheroids for Psoriasis Therapy at SID Annual Meeting - Nasdaq
Revolutionary Fibroblast Treatment Shows Promise for Long-lasting Psoriasis Relief, New Data Reveals - Stock Titan
Raymond James Financial Inc. Takes $37,000 Position in FibroBiologics, Inc. (NASDAQ:FBLG) - Defense World
FibroBiologics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
FibroBiologics, Inc. Reports First Quarter 2025 Financial Results and Operational Milestones - Nasdaq
FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
FibroBiologics Earnings: Net Loss Drops 41%, Clinical Trial Launch Set for Breakthrough Wound Treatment - Stock Titan
FibroBiologics, Inc. SEC 10-Q Report - TradingView
FibroBiologics (FBLG) Projected to Post Earnings on Tuesday - Defense World
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn Inc.
1.44%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):